to establish the utility of neuronal cell implant in patients with established stroke deficits , a study was undertaken with a randomized , open - label trial with observer - blind neurologic evaluation of patients with a cerebral infarction involving the basal ganglia region of the brain who receive stereotactic injections of hnt neuronal cells . substantial fixed motor deficit following stroke is a significant medical problem that needs to be better addressed . currently , rehabilitation is the only widely practice therapy . although fetal tissue is being utilized for the treatment of some neurologic diseases , logistical and ethical problems may hinder its widespread use for neural transplantation . the use of alternative graft sources such as lbs - neurons and other cells ( see below ) is therefore appealing . hnt neuronal cells , licensed from the university of pennsylvania , are human neuronal cells derived from a single cell line . through eight years of in vitro and in vivo preclinical testing , the cells have been demonstrated to be human , fully post - mitotic , non - tumorigenic neuronal cells which demonstrate efficacy in animal models . after safety studies were performed in mice , rats and primates , implantation of human neurons into rats with basal ganglia stroke showed both motor and behavioral recovery in comparison to sham controls . a second experiment shows that the number of cells implanted correlated with the degree of recovery . the first clinical study evaluated the product as a somatic cell therapy that produced a novel way to restore lost cognitive and motor function . further , early research is being planned in the use of hnt neuronal cells as a platform for the introduction and expression of specific human neuronal genes into the brain for the treatment of neurologic disorders . hnt neuronal cells were derived by treating the neuronal precursor cell line nt2 / d1 derived from an embryonic carcinoma with retinoic acid and mitotic inhibitors . following treatment with retinoic acid , the nt2 / d1 cells differentiate into non - proliferating , terminally differentiated neurons and proliferating non - neuronal accessory cells ( andrews , p . w . dev . biol . 103 : 285 - 293 , 1984 ). after subsequent treatment with mitotic inhibitors ( cytosine arabinoside and fluorodeoxyuridine ), pure cultures of post - mitotic human neuronal cells result ( pleasure and lee , 1993 ). these cells were then suspended in freezing medium ( has , dmso and pbs ) and frozen in ampoules . the resultant product , when produced in compliance with current good manufacturing practice ( cgmp ) guidelines , is called lbs - neurons human neuronal cells . the nt2 / d1 cell line was established in culture as a cell line by dr . peter andrews at the wistar institute in philadelphia during the early 1980s . dr . andrews received the original cells ( known as tera - 2 ) from dr . jourgen fögh of the sloan kettering institute in new york city . the tera - 2 cells had been isolated from a pulmonary embryonic carcinoma of a 22 - year - old caucasian male with a metastasized primary testicular germ cell tumor . the post - mitotic human neuronal cells available as hnt neuronal cells resulted from the differentiation of nt2 / d1 cells in response to retinoic acid . these human neuronal cells actively demonstrate neurite outgrowth , sending out numerous processes that assemble into neuronal networks . they also form polarized processes that have been identified functionally as axons and dendrites , and demonstrate the ability to form synapses upon maturation . these cells have retained their human characteristics as demonstrated by isoenzyme typing , expression of a variety of human antigens , and by karyotyping ( andrews et al ., ibid ., miyazono et al ., 1996 , layton bioscience , inc ., 1996 ). furthermore , hnt cells have been successfully implanted in various animal models where they histologically integrated with the neurons and sent processes into adjacent tissue . a recent report describes the results of transplanting hnt cells in rats with sustained ischemic damage . transplants of 0 , 5 , 10 , 20 , 40 , 80 or 160 × 10 3 neurons produced dose - dependent improvement in function and hnt survival . animals receiving 40 , 80 or 160 × 10 3 neurons produced a dose - dependent improvement in both passive avoidance and elevated body swing tests . transplants of 80 or 160 × 10 3 hnt neurons demonstrated a 12 - 15 % survival of hnt neurons in the graft , while transplants of 40 × 10 3 hnt neurons resulted in a 5 % survival . moreover , similar improvement was seen in rats with cerebral ischemia induced by occlusion of the middle cerebral artery . the viability and survival of hnt neurons were evaluated before transplantation and at three month after transplantation in ischemic rats . monthly behavioral tests ( 1 , 2 and 3 months after implant ) showed that ischemic animals receiving intrastriatal implants ( about 4 × 10 cells ) displayed normalization of asymmetrical motor behavior compared with ischemic animals that received medium alone . within - subject comparisons of cell viability and subsequent behavioral changes revealed that a high cell viability just prior to transplantation surgery correlated highly with a robust and sustained functional improvement in the transplant recipient . there also was a positive correlation between the number of surviving hnt neurons and the degree of functional recovery ( borlongan c v et al . neuroreport 9 ( 12 ): 2837 - 42 , 1998 ). other cells may be used in the transplant procedures disclosed herein , provided they meet the following criteria : non - immunogenic , non - tumorigenic , reproducible , adapting to the transplant location and synapsing with the local neurons . the following are only a few examples of cells that could be readily tested according to the procedures given in this patent application . the hcn - 1 cell line is derived from parental cell lines from the cortical tissue of a patient with unilateral megalencephaly growth ( ronnett g . v . et al . science 248 : 603 - 5 , 1990 ). hcn - 1a cells have been induced to differentiate to a neuronal - like morphology and stain positively for neurofilament , neuron - specific enolase and p75ngfr , but not for myelin basic protein , s - 100 or glial fibrillary acidic protein ( gfap ). because these cells also stain positively for γ - amino butyric acid and glutamate , they appear to become neuro - transmitting bodies . earlier poltorak m et al . ( cell transplant 1 ( 1 ): 3 - 15 , 1992 ) observed that hcn - 1 cells survived in the brain parenchyma and proposed that these cells may be suitable for intracerebral transplantation in humans . ronnet g v et al . ( neuroscience 63 ( 4 ): 1081 - 99 , 1994 ) reported that hcn - 1 cells grew processes resembling neurons when exposed to nerve growth factor , dibutyryl cyclic amp and isobutylmethylxanthine . the nerve cells also can be administered with macrophages that have been activated by exposure to peripheral nerve cells . such activated macrophages have been shown to clean up the site of cns trauma , for example , a severed optic nerve , after which new nerve extensions started to grow across the lesion . implanting macrophages exposed to cns tissue ( which secretes a chemical to inhibit macrophages ) or nothing at all resulted in little or no regeneration ( lazarov - spiegler et al . faseb j . 10 : 1 , 1996 ). sertoli cells have been disclosed in u . s . pat . no . 5 , 830 , 460 to university of south florida as producing a sustained localized brain immunosuppressive effect on transplantation into the brain tissue . hybrid sertoli - secretory cells disclosed in u . s . pat . no . 5 , 827 , 736 also can be useful in the present invention , where the stroke destroys secretory cells . u . s . pat . no . 5 , 753 , 505 to emory university discloses a cellular composition which is greater than about 90 % mammalian , non - tumor - derived , neuronal progenitor cells which express a neuron - specific marker and which can give rise to progeny which can differentiate into neuronal cells . the cells are proposed for treatment of neuronal disorders . u . s . pat . no . 5 , 753 , 491 discloses human fetal neuro - derived cells lines as well as method of implanting the immortalized cells into a host . the cells are provided with a heterologous nucleic acid for a biologically active peptide , such as tyrosine hydroxylase . the cells may be delivered with other cells , such as hnt cells or pc12 cells . gage et al . ( u . s . pat . no . 5 , 766 , 948 and others ) has disclosed methods for producing a neuroblast and a cellular composition which is an enriched population of neuroblast cells . these cells can be used to treat neuronal disorders . u . s . pat . no . 5 , 411 , 883 also discloses procedures for isolation and proliferation of neuron progenitor cells , their growth , storage , production and implantation of proliferated neuron progenitor cells . the cells are obtained from a donor &# 39 ; ventral mesencephalon at the appropriate stage of embryonic development . the cells differentiate to produce dopamine . fetal pig cells have been implanted into patients with neurodegenerative diseases , such as parkinson &# 39 ; s disease and huntington &# 39 ; s chorea , and intractable seizures , in whom surgical removal of the excited area would otherwise have been performed . such cells , if properly screened for retroviruses , could also be used in the inventive method . neural crest cells were isolated and cultured according to stemple and anderson ( u . s . pat . no . 5 , 654 , 183 ), which is incorporated herein by reference , with the modification that basic fibroblast growth factor ( bfgf ) is added to the medium at concentrations ranging from 5 to 100 ng / ml in 5 ng / ml increments . neural crest cells so cultured were found to be stimulated by the presence of fgf in increasing concentrations about 1 or 5 ng / ml . such cells differentiate into peripheral nerve cells , which can be used in the instant invention . neural cells with stem cell properties have been isolated by snyder et al ., from the human fetal brain and propagated in vitro by a variety of equally effective and safe means — both epigenetic ( e . g ., with mitogens such as epidermal growth factor ( egf ) or basic fibroblast growth factor ( bfgf ) or with membrane substrates ) and genetic ( e . g ., with propagating genes such as vmyc or large t - antigen ) ( flax , j d et al ., nature biotechnology 16 : 1033 - 39 , 1998 ). murine neural stem cells ( nscs ) were recently administered to adult rats whose middle cerebral artery ( mca ) was obstructed to produce experimental and dramatic cerebral tissue loss ( see fig1 a ). fig1 a shows an infarcted rat brain , into which vehicle alone had been injected intracerebrally . the large infarct cavity ( white arrowhead ) represents significant tissue loss . fig1 b is a photo of a rat brain subjected to a similar infarct but treated three days later with a cisternal ( region indicated by black arrow ) infusion of a cellular suspension of murine nscs plus basic fibroblast growth factor ( bfgf ), which is a significant distance from the region of infarction . nevertheless , the nscs appear to have migrated to the region of damage and significantly ameliorated the cerebral volume loss ( white arrowhead ), appearing to have helped “ fill in ” the infarction cavity and reverse the tissue loss . in preliminary studies , animals treated in this manner showed a significant improvement in cortically mediated behavioral tasks . therefore , these results indicate that nsc were drawn to stroke injuries in adult cns . it may be beneficial to administer certain cytokines , growth factors and drugs in the transplant area . such moieties are optionally used or may be administered concomitantly with the transplant or later . known cytokines include interleukins ( il ) il - 1 , il - 2 , il - 3 , il - 4 , il - 5 , il - 6 , il - 7 , il - 8 , il - 10 , and il - 11 ; tissue necrosis factors ( tnf ), tnfα and tnfβ , also lymphotoxin ( lt ); interferons ( ifn ) ifnα , ifnβ and ifnγ ; tissue growth factor ( tgf ); and basic fibroblast growth factor ( bfgf ). the colony - stimulating factors ( csfs ) are specific glycoproteins that are thought to be involved in the production , differentiation and function of stem cells . nerve growth factor ( ngf ) has been shown to increase the rate of recovery in spatial alternation tasks after entorhinal lesions , possibly by acting on cholinergic pathways ( stein and will , brain res . 261 : 127 - 31 , 1983 ). in addition , cyclosporine was used for at least part of the pre - and post - implant period and other similarly active compounds could be substituted . cyclosporine was withdrawn in on patient because of seizures , and no marked diminution in function occurred thereafter . therefore , immunosuppressive therapy may not be necessary , or perhaps could be confined only to the perioperative period . because earlier studies ( have shown that hnt human neuronal cells and some of the above mentioned cells adapt to their surroundings , other uses are highly likely . these include but are not limited to parkinson &# 39 ; s disease , huntington &# 39 ; s disease , brain injury ( traumatic or other causes ) and others . stereotactic implant procedures for some of these disorders , using fetal cells , are well established . observer - blinded determination of neurologic status was performed , including evaluation of the functional deficit , contrast - enhanced magnetic resonance image ( mri ) scanning to measure the volume of blood - brain barrier alteration at the target site ( as an indirect measure of inflammatory response ), and positron emission tomography ( pet ) with fluorodeoxyglucose ( fdg ) scan for assessment of regional brain metabolism . this procedure was modified from that of brott t , adams h p , olinger c p , et al . ( 1989 ) measurements of acute cerebral infarction : a clinical examination scale . stroke 20 : 864 - 870 . stroke scale items were administered in the order listed below . performance was recorded in each category after each subscale exam . personnel were forbidden from going back and changing scores . specific directions were provided for each exam technique . this procedure was adapted from that reported in hantson l , de weerdt w , de keyser j , et al . ( 1994 ) the european stroke scale . stroke 25 : 2215 - 2219 . a score of 10 is assigned alert , keenly responsive patients ; a score of 8 to drowsy patients who can be aroused by minor stimulation to obey , answer or respond ; a score of 6 to patients who require repeated stimulation to attend , or are lethargic or obtunded and require strong or painful stimulation to move ; a score of 4 to patients who cannot be aroused by any stimulation but react purposefully to painful stimuli ; a score of 2 to patients who cannot be aroused by any stimulation and react decerebrately to painful stimuli ; and a score of 0 to patients who cannot be aroused by any stimulation and do not react to painful stimuli . the examiner , without demonstrating , verbally gives the patient the following commands : 1 . stick out your tongue . 2 . put your finger ( of the unaffected side ) on your nose . 3 . close your eyes . the examiner has a conversation with the patient ( how is the patient feeling , did he / she sleep well , how long has the patient been in the hospital . . . ) and scores the patient as follows : normal speech ( 8 ), slight word - finding difficult but possible conversation ( 6 ), severe word - finding difficulties with difficult conversation ( 4 ), only yes or no ( 2 ), and mute ( 0 ). the examiner stands at arm &# 39 ; s length and compares the patient &# 39 ; s field of vision by advancing a moving finger from the periphery inward . the patient fixates on the examiner &# 39 ; s pupil , first with one and then with the other eye closed . normal is 8 and deficit is 0 . the examiner steadies the patient &# 39 ; s head and asks him / her to follow the examiner &# 39 ; s moving finger . the examiner observes the resting eye position and subsequently the full range of movements by moving the index finger from the left to the right and back . normal is 8 , median eye position with impossible deviation to one side ( 4 ), lateral eye position with possible return to midline ( 2 ), and lateral eye position without return to midline ( 0 ). the examiner observes the patient as he / she talks and smiles , noting any asymmetrical elevation of one corner of the mouth or flattening of the nasolabial fold . only the muscles of the lower half of the face are assessed . normal is 8 , paresis 4 , and paralysis 0 . the examiner asks the patient to close his / her eyes and actively lifts the patient &# 39 ; s arms into position so that they are outstretched at 45 ° in relation to the horizontal plane with both hands in mid - position so that the palms face each other . the patient is asked to maintain this position for 5 seconds after the examiner releases the arms . only the affected side is evaluated . score is 4 for maintaining arm position for 5 sec ; 3 is maintaining position for 5 sec with hand pronation ; score is 2 if arm drifts before 5 sec and maintains a lower position ; score is 1 if arm cannot maintain position but attempts to oppose gravity ; and 0 if arm falls . the patient &# 39 ; s arm is rested next to the leg with the hand in mid - position . the examiner asks the patient to raise the arm outstretched to 90 ° ( 4 ), if the arm is straight but movement is not full ( 3 ), flexed arm ( 2 ), trace movements ( 1 ), or no movement ( 0 ). the patient is tested with the forearm supported and the hand unsupported , relaxed in pronation . the patient is asked to extend the hand . normal , fully isolated movement with no decrease in - strength is 8 , full isolated movement with reduced strength is 6 , movement not isolated and / or full is 4 , trace movement is 2 , and no movement is 0 . the examiner asks the patient to form with both hands , as strongly as possible , a pinch grip with the thumb and forefinger on the same hand and to try to resist a weak pull . the examiner checks the strength of this grip by pulling the pinch with one finger . equal strength is 8 , reduced strength on the affected side is 4 , and pinch grip impossible on affected side is 0 . the examiner actively lifts the patient &# 39 ; s affected leg into position so that the thigh forms an angle of 90 ° with the bed . the examiner asks the patient to close his / her eyes and to maintain this position for 5 seconds without support . leg maintains position for 5 sec ( 4 ), leg drifts to intermediate position by 5 sec ( 2 ), leg drifts to bed within 5 sec but not immediately ( 1 ), and leg falls to bed immediately ( 0 ). the patient is supine with the legs outstretched . the examiner asks the patient to flex the hip and knee . normal movement is 4 , movement against resistance with reduced strength is 3 , movement against gravity is 2 , trace movement is 1 , and no movement is 0 . the patient is tested with the leg outstretched . the examiner asks the patient to dorsiflex the foot . normal ( e . g ., outstretched , full movement , normal strength ) is 8 , leg outstretched with full movement but reduced strength is 6 , leg outstretched with less than full movement or flexed knee or supinated foot is 4 , trace movement is 2 , and no movement is 0 . a normal gait scores 10 , gait with abnormal aspect and / or limited distance or speed is 8 , walking with aid is 6 , requiring the assistance of one or more persons is 4 , no walking but standing supported is 2 , and no walking or standing is 0 . this test has been modified from that described in mahoney f i , barthel d w . ( 1965 functional evaluation : the barthel index . md state med j 14 : 61 - 65 ). it includes a number of life activities , including feeding getting out of and returning to bed , toilet activities , walking , handling stairs , dressing , controlling bowel and bladder . this survey has been modified from ware j e , sherbourne c d . ( 1992 ) the mos 36 - item short - form health survey ( sf - 36 ). 1 . conceptual framework and item selection . med care 30 : 473 - 483 . it includes general health , comparison to a year earlier , competence at daily activities , ability to work , and emotional status , patients with stable strokes and fixed deficits were recruited for a phase i safety trial . inclusion criteria included major motor deficit from completed basal ganglia stroke defined on imaging . the permissible duration of stroke was six months to six years , with a required fixed deficit without substantial change for at least two months . patient age could range from 40 to 75 years inclusive . the patient also had to be able to provide informed consent . patients must have had a motor deficit such as hemiparesis following a completed basal ganglia infarction ( 4 - 15 mm ) involving gray matter as defined on ct or mr imaging scan and by clinical syndromes of lacunar infarction ( e . g ., hemiparesis with ataxia in the same limb , pure motor hemiplegia ). a substantial deficit was defined by a total score of 70 or less on the european stroke scale ( see infra ). preoperative investigations included serial stroke scales ( three ) over two months prior to surgery . imaging studies included mri scan , fdg - pet studies as well as functional mri . quality of life scales with the barthel index and the sf36 as well as serologic tests and video taping were performed . postoperative investigations included clinical assessments and stroke scales at regular intervals over the first year with serologic tests , mri scans and research mri scans as well as pet scans at six and 12 months . for immunosuppression patients received 6 mg / kg of cyclosporine - a per day , administered orally once daily . however , the dose was adjusted according to the results of serum levels . the drug was administered beginning one week prior to surgery and continued for eight weeks after surgery . methylprednisolone ( 40 mg iv ) also was administered during surgery . prohibited medications ( for at least 1 week prior to surgery ) were all products with anticoagulant or anti - platelet activity , including warfarin , aspirin , nonsteroidal anti - inflammatory drugs ( nsaids ), and ticlopidine . these medications were allowed to be restarted 24 hours after surgery . on the morning of surgery , cells were prepared for implantation . one ml frozen lbs - neurons cryoampules had been filled with a suspension containing 6 . 0 × 10 6 human neuronal cells per ml . it is important to thaw the neurons no more than one hour prior to use , because their viability begins to decrease after 2 hours on ice in phosphate buffer solution . it takes approximately 30 - 45 minutes to prepare the cells for injection . the cryopreserved suspension stored frozen at − 170 ° c ., thawed rapidly in a 37 ° c . water bath with gentle agitation until the contents were just liquefied . the suspension was gently mixed to resuspend the cells . to maintain sterile conditions , gowned and gloved personnel performed the ensuing steps under a hood . the thawed cell suspension was transferred from the cryovials to sterile 15 ml centrifuge tubes containing isolyte ® s , ph 7 . 4 ( multi - electrolyte injection , mcgaw inc ., irvine , calif . ), centrifuged at 200 xg for 7 minutes at room temperature and the cell pellet gently resuspended in isolyte s . this wash of the cells was repeated twice . for the final wash , all cells from different tubes were pooled together into one tube . next a sample of the lbs - neuron suspension was diluted in 0 . 4 % trypan blue , and viable and dead cells counted using phase contrast microscopy . the cell concentration was calculated based on the total viable cell count . the pellet volume was measured , and the cells resuspended to a final concentration of 3 . 3 × 10 7 cells / ml in isolyte s and aliquoted at 120 μl per sterile 1 . 0 ml vial . depending on the dose to be administered , one or more vials were prepared . vial ( s ) were loaded into a closed holder and carried by hand in an upright position to the operating room for immediate use . the cells were administered ( in up to three tracts ) by direct stereotactic injection . the first four patients received two million cells in three implants on one track , and the next eight patients were randomized to receive two or six million cells in three or nine implants , respectively . aliquots of cells that were placed in culture and not implanted showed robust development of neuronal processes with 24 hours . patients stopped all anticoagulant medications and started cyclosporine one week prior to surgery . surgery began with stereotactic frame application under local anesthesia and mild sedation . stereotactic instrumentation consisted of the following : leksell model g stereotactic coordinate frame ( elekta instruments , atlanta , ga .) and a 0 . 9 mm outer diameter stereotactic aspiration / injection cannula . contrast - enhanced computed tomography ( ct ) stereotactic targeting of the stroke area was performed with 5 - millimeter slices through the brain . coronal and sagittal views were used to define a safe trajectory that entered a cortical gyrus . and spared a sulcus . stereotactic coordinates were obtained for each instrument placement . three points in the basal ganglia were a ) inferior to the stroke , b ) within the midportion of the stroke , and c ) in the superior aspect of the basal ganglia either within or beyond the stroke . for patients receiving nine implants ( 6 × 10 6 cells ), three trajectories were chosen in the same paramedian plane , spaced by 5 - 6 mm at the target . a twist drill or burr hole skull opening was made . the dura was opened and a 1 . 8 - mm , 15 - cm length stabilizing probe inserted to a point 4 cm proximal to the final target . a cannula with a 0 . 9 - mm outer diameter was then inserted down to the deepest target point for the first implantation . the first inner cannula used had an internal volume of 100 μl ; a second cannula designed later had a volume of 20 μl ( synergetics , st . louis , mo .). in the operating room , the cells were aspirated into a 250 μl syringe . the internal volume of the cannula was filled with the cell suspension , and then a 20 μl volume of cells was injected slowly at the first target site . the instrument was then withdrawn to the second and third sites for subsequent implants . after the three implants were made , the cannula was withdrawn from the brain . the wound was either closed or the next vial of cells prepared to inject implants 4 - 9 in those patients who received 6 × 10 6 cells . following surgery , a post - operative ct scan confirmed the absence of hemorrhage . a postoperative ct scan confirmed the safety of the procedure . all patients were then observed overnight and discharged home the next morning . no new neurological deficits were identified acutely . all 12 patients were discharged within 24 hours . follow - up assessments for safety and efficacy were made at 1 week , 1 month , 2 months , 3 months , 6 months , and then yearly ( beginning with the 12 month visit ) including an observer - blind neurologic examination for evaluation of the functional deficit and safety ( including adverse events and follow - up laboratory tests ). contrast - enhanced mr imaging was used to measure the volume of blood brain barrier alteration at the target site and pet scanning was used for assessment of regional brain metabolism . by the end of the study , nine male patients and three female patients had been admitted and received implants . their age range was 44 to 75 years . the age of the stroke varied from seven months to 55 months . all strokes were confirmed to be in the basal ganglia location , and cells were placed only in that location . four patients had involvement of adjacent cerebral cortex . measures of efficacy were scores on the european stroke scale ( ess ), national institutes of health stroke scale ( nihss ), barthel index ( bi ) and short form 36 health survey ( sf - 36 ) collected pre - operatively , on the day of surgery ( baseline ) and at predetermined intervals through 12 months following implantation of lbs - neurons . higher scores on the ess , bi and sf - 36 indicate better performance , and lower scores on the nihss indicate better performance . for this report , 6 - months post - implantation was the primary time point analyzed . at 6 months following implantation , 6 of the 12 patients treated ( 50 %) had scores on the ess that were higher than baseline ( range : 3 to 10 points ), 3 patients were unchanged and 3 patients deteriorated ( range : − 1 to − 3 points ) compared to their baseline scores . five patients ( 42 %) had an improvement of at least 5 points on the ess . the mean change in ess score from baseline to week 24 for all implanted patients was 2 . 2 points , a difference that was statistically significant ( p ≧ 0 . 05 ). in the group of patients who received 2 million cells , 3 of 8 patients improved from baseline to week 24 ( range : 3 to 8 points ), 3 patients were unchanged , and 2 patients deteriorated ( range : − 1 to − 3 points ). in the 6 - million dose group , 3 of 4 patients improved ( range , 5 to 10 points ) and one patient worsened (− 2 points ). the mean change from baseline to week 24 was 1 . 8 points in the 2 - million group and 5 . 3 points in the 6 - million group . the change within each treatment group was not statistically significant ( p ≧ 0 . 139 ). nihss scores reflected similar changes in functional performance as seen on the ess . at the 6 - month follow - up evaluation , 8 patients had improved scores on the nihss ( range : − 1 to − 4 points ), 1 patient was unchanged and 3 patients deteriorated ( range : 1 to 2 points ) compared to their baseline scores . in the 2 - million group , 5 of 8 patients improved from baseline to week 24 ( range : − 1 to − 4 points ) and in the 6 - million dose group , 3 of 4 patients improved (− 1 point each ). the mean change in nihss score from week 0 to week 24 was − 0 . 5 points for the 2 - million group and − 0 . 3 for the 6 - million group . changes from baseline on the nihss were not statistically significant . the bi and sf - 36 did not detect substantial change in patient function . motor elements of the ess ( ess - motor ) accounted for the majority of the change noted in patients treated with hnt neurons . the mean change in ess - motor score for all patients treated with hnt neurons was 2 . 5 ( p = 0 . 026 ). four patients ( 33 %) had a change of at least 6 points on the ess - motor . by dose group , the mean change in ess - motor score was 1 . 9 for the 2 - million group ( p = 0 . 186 ) and 3 . 8 for the 6 - million group ( p = 0 . 080 ). pet scans performed at baseline and at week 24 showed that 6 of 11 patients had and improvement in cerebral glucose metabolism as indicated by fluorodeoxyglucose ( fdg ) uptake . one patient (# 012 ) had not had a week - 24 pet scan at the time of this report . the pet scan findings appeared to correlate with the clinical findings of neurologic improvement . of the 6 patients with an increase in fdg uptake of at least 15 %, 4 ( 67 %) patients improved 3 points or more on the ess from baseline to week 24 , and 2 patients ( 33 %) were essentially unchanged ( 0 and − 1 point change ). of those patients with less than 15 % increase in fdg uptake , 4 of 5 ( 80 %) did not improve on the ess and 1 patient improved by 5 points . there were no deaths , treatment - related serious adverse events , or early withdrawals due to adverse events . the majority of adverse events were considered mild ; and the most common adverse events were fatigue , headache , nausea , and urinary tract infection . events that were considered severe included constipation , exacerbation of chronic renal failure , increased creatinine , vomiting and dehydration , urinary tract infection , and kidney stones . there were several adverse events that were considered probably related to treatment ; and all were common surgical adverse events such as headache , nausea , vomiting , blood loss with removal of the stereotactic frame and pain at the surgical site . four patients had serious adverse events , none of which was considered by the investigator to be related to implantation of hnt neurons . one patient with diabetes had an exacerbation of his chronic renal failure while on cyclosporine , one patient had a single seizure 5 months after implantation , and one patient at 6 months after implantation had a new right pontine infarction that was contralateral to the implantation site . no clinically significant laboratory , radiographic , or electrocardiographic abnormalities were identified that could be attributed to the hnt neurons . cyclosporine immunosuppression was well tolerated except by one patient whose baseline serum creatinine should have excluded him from the study . serum measures of immunologic reaction showed only minor changes that may have been indicative of a mild inflammatory reaction related to the surgical procedure itself . serial mri scans did not show evidence of substantial edema , inflammation , or breakdown of the blood brain barrier within or adjacent to the site of implantation . systolic blood pressure was moderately reduced post - implantation in the 2 - million cell group , but not in the 6 - million cell group , and diastolic blood pressure and heart rate were not appreciably affected . none of the vital sign changes was statistically significant . the results of this study demonstrate that it is possible to safely implant hnt neurons into the basal ganglia of patients with strokes , and that these cells do not elicit an immunologic or toxic reaction within the cns or systemically . although the small number of patients treated precludes definitive conclusions , the stroke scale results suggest that these cells may be efficacious and that the higher dose administered may be more efficacious than the lower dose . the feasibility and preliminary safety data from this study provide the basis for the design and conduct of additional clinical trials with lbs - neurons .
a method of treating stroke in a patient who has undergone a stroke comprising administering at least 2 million suitable neuronal cells to at least one brain area involved in the stroke . the method comprises the step of using a twist drill or a burr to form a hole in the skull through which the cells could be administered . exemplary cells are hnt neuronal cells , hcn - 1 cells , fetal pig cells , neural crest cells , neural stem cells , or a combination thereof . also disclosed herein is a pharmaceutical composition of 95 % pure hnt neuronal cells , which composition further includes a vial containing pbs and human neuronal cells . this vial is provided in a container with liquid nitrogen , whereby the composition is frozen and maintained at − 170 ° c . before use . also disclosed are methods of improving speech , cognitive , sensory , and motor function in a person who has experienced brain damage which interferes with function by administering a sterile composition of a sufficient number of neuronal cells or neural stem cells to the damaged area . also disclosed is a method of replacing central nervous cells lost to neurodegenerative disease , trauma , ischemia or poisoning .